View More Recent Stories

Jul 14, 2022 04:05PM Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma
Jul 11, 2022 06:30AM Flagship Pioneering Launches Apriori Bio to Provide Variant-Proof Protection from the Greatest Viral Threats
Jun 30, 2022 07:01AM Omega Therapeutics (OMGA) Reports Preclinical Data Supporting OTX-2002
Jun 30, 2022 07:00AM Omega Therapeutics Presents New Preclinical Data Supporting the First Epigenomic Controller, OTX-2002, as a Potential Therapeutic Approach in Hepatocellular Carcinoma at the ESMO 2022 World Congress o
Jun 23, 2022 07:06AM Omega Therapeutics to Present New Preclinical Data for the First Epigenomic Controller, OTX-2002, for Hepatocellular Carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gast
Jun 15, 2022 07:18AM Omega Therapeutics (OMGA) Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma
Jun 15, 2022 07:00AM Omega Therapeutics Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma
Jun 2, 2022 07:00AM Omega Therapeutics to Participate in the Jefferies Healthcare Conference and Goldman Sachs 43rd Annual Global Healthcare Conference in June 2022
May 4, 2022 04:01PM Omega Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
May 3, 2022 07:00AM Omega Therapeutics to Unveil Preclinical Data on Epigenomic Programming of MYC with Epigenomic Controllers as a Promising Therapeutic Approach in Non-Small Cell Lung Cancer at the 25th Annual ASGCT Me
Apr 29, 2022 07:02AM Omega Therapeutics (OMGA) Appoints Joshua Reed as CFO
Apr 29, 2022 07:00AM Omega Therapeutics Announces Appointment of Joshua Reed as Chief Financial Officer
Apr 8, 2022 01:05PM Omega Therapeutics Presents Preclinical Data on OTX-2002, First-in-Class Epigenomic Controller, as Potential Treatment for Hepatocellular Carcinoma at the AACR Annual Meeting 2022
Mar 30, 2022 07:00AM Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth
Mar 10, 2022 07:00AM Omega Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Outlines Key Corporate Objectives for 2022
Mar 8, 2022 05:05PM Omega Therapeutics to Present Preclinical Data for OTX-2002 at the American Association for Cancer Research Annual Meeting 2022
Mar 2, 2022 06:00AM Flagship Pioneering Unveils Vesalius Therapeutics to Revolutionize the Treatment of the Diseases that Drive Ninety Percent of Human Illness
Jan 26, 2022 09:31AM Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform Biology
Jan 10, 2022 07:01AM Omega Therapeutics (OMGA) Appoints Yan Moore as CFO
Jan 10, 2022 07:00AM Omega Therapeutics Announces Appointment of Yan Moore, M.D., as Chief Medical Officer
Nov 18, 2021 07:00AM Omega Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
Nov 18, 2021 05:00AM Generate Biomedicines Announces First External Equity Raise of $370 Million to Advance Its Drug Generation Platform
Nov 10, 2021 07:00AM Omega Therapeutics Reports Third Quarter 2021 Financial Results and Outlines Key Corporate Objectives
Nov 9, 2021 07:00AM Omega Therapeutics to Present at the Jefferies London Healthcare Conference
Oct 14, 2021 07:00AM Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine
Sep 27, 2021 07:00AM Omega Therapeutics to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference
Sep 10, 2021 07:00AM Omega Therapeutics Reports Second Quarter 2021 Financial Results and Outlines Key Corporate Objectives
View More Recent Stories